147 related articles for article (PubMed ID: 34176597)
21. Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT - AF Registry.
Perino AC; Shrader P; Turakhia MP; Ansell JE; Gersh BJ; Fonarow GC; Go AS; Kaiser DW; Hylek EM; Kowey PR; Singer DE; Thomas L; Steinberg BA; Peterson ED; Piccini JP; Mahaffey KW
J Am Heart Assoc; 2019 May; 8(9):e011205. PubMed ID: 31023126
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: perspectives from the observational, prospective WATER Registry.
Turk UO; Tuncer E; Alioglu E; Yuksel K; Pekel N; Ozpelit E; Vuran O; Tengiz I
Cardiol J; 2015; 22(5):567-75. PubMed ID: 26100825
[TBL] [Abstract][Full Text] [Related]
23. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
[TBL] [Abstract][Full Text] [Related]
24. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
[TBL] [Abstract][Full Text] [Related]
25. Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study.
Chan EW; Lau WC; Siu CW; Lip GY; Leung WK; Anand S; Man KK; Wong IC
Heart Rhythm; 2016 Aug; 13(8):1581-8. PubMed ID: 27033342
[TBL] [Abstract][Full Text] [Related]
26. Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF).
Madhavan M; Holmes DN; Piccini JP; Freeman JV; Fonarow GC; Hylek EM; Kowey PR; Mahaffey KW; Pieper K; Peterson ED; Chan PS; Allen LA; Singer DE; Naccarelli GV; Reiffel JA; Steinberg BA; Gersh BJ;
Am J Cardiol; 2020 Oct; 132():66-71. PubMed ID: 32826041
[TBL] [Abstract][Full Text] [Related]
27. Racial Differences in Quality of Anticoagulation Therapy for Atrial Fibrillation (from the TREAT-AF Study).
Yong C; Azarbal F; Abnousi F; Heidenreich PA; Schmitt S; Fan J; Than CT; Ullal AJ; Yang F; Phibbs CS; Frayne SM; Ho PM; Shore S; Mahaffey KW; Turakhia MP
Am J Cardiol; 2016 Jan; 117(1):61-8. PubMed ID: 26552504
[TBL] [Abstract][Full Text] [Related]
28. Use of the SAMe-TT2R2 Score to Predict Good Anticoagulation Control with Warfarin in Chinese Patients with Atrial Fibrillation: Relationship to Ischemic Stroke Incidence.
Chan PH; Hai JJ; Chan EW; Li WH; Tse HF; Wong IC; Lip GY; Siu CW
PLoS One; 2016; 11(3):e0150674. PubMed ID: 27010633
[TBL] [Abstract][Full Text] [Related]
29. Warfarin for atrial fibrillation in community-based practise.
Rose AJ; Ozonoff A; Henault LE; Hylek EM
J Thromb Haemost; 2008 Oct; 6(10):1647-54. PubMed ID: 18853483
[TBL] [Abstract][Full Text] [Related]
30. Anticoagulation Control, Outcomes, and Associated Factors in Patients with Atrial Fibrillation Receiving Warfarin at Tertiary Care Hospital in Ethiopia.
Yimer NS; Abiye AA; Hussen SU; Tadesse TA
Clin Appl Thromb Hemost; 2021; 27():10760296211049786. PubMed ID: 34724849
[TBL] [Abstract][Full Text] [Related]
31. Quality of Warfarin Anticoagulation in Indigenous and Non-Indigenous Australians With Atrial Fibrillation.
Nguyen MT; Gallagher C; Pitman BM; Emami M; Kadhim K; Hendriks JM; Middeldorp ME; Roberts-Thomson KC; Mahajan R; Lau DH; Sanders P; Wong CX
Heart Lung Circ; 2020 Aug; 29(8):1122-1128. PubMed ID: 31980393
[TBL] [Abstract][Full Text] [Related]
32. Body Mass Index and Adverse Outcomes in Elderly Patients With Atrial Fibrillation: The AMADEUS Trial.
Senoo K; Lip GY
Stroke; 2016 Feb; 47(2):523-6. PubMed ID: 26628383
[TBL] [Abstract][Full Text] [Related]
33. NOAC or Warfarin for Atrial Fibrillation: Does Time in Therapeutic Range Matter?
Merinopoulos I; Venables P; Chalmers I; Vassiliou V
Recent Adv Cardiovasc Drug Discov; 2015; 10(1):60-4. PubMed ID: 26365270
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.
Wallentin L; Lopes RD; Hanna M; Thomas L; Hellkamp A; Nepal S; Hylek EM; Al-Khatib SM; Alexander JH; Alings M; Amerena J; Ansell J; Aylward P; Bartunek J; Commerford P; De Caterina R; Erol C; Harjola VP; Held C; Horowitz JD; Huber K; Husted S; Keltai M; Lanas F; Lisheng L; McMurray JJ; Oh BH; Rosenqvist M; Ruzyllo W; Steg PG; Vinereanu D; Xavier D; Granger CB;
Circulation; 2013 Jun; 127(22):2166-76. PubMed ID: 23640971
[TBL] [Abstract][Full Text] [Related]
35. Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range.
Razouki Z; Ozonoff A; Zhao S; Jasuja GK; Rose AJ
Circ Cardiovasc Qual Outcomes; 2014 Sep; 7(5):664-9. PubMed ID: 25185245
[TBL] [Abstract][Full Text] [Related]
36. The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation.
Vinding NE; Bonde AN; Rørth R; Lamberts M; Olesen JB; Gislason GH; Torp-Pedersen C; Køber L; Fosbøl EL
Europace; 2019 Apr; 21(4):572-580. PubMed ID: 30508073
[TBL] [Abstract][Full Text] [Related]
37. Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation.
Williams BA; Evans MA; Honushefsky AM; Berger PB
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29025746
[TBL] [Abstract][Full Text] [Related]
38. Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
Westenbrink BD; Alings M; Granger CB; Alexander JH; Lopes RD; Hylek EM; Thomas L; Wojdyla DM; Hanna M; Keltai M; Steg PG; De Caterina R; Wallentin L; van Gilst WH
Am Heart J; 2017 Mar; 185():140-149. PubMed ID: 28267467
[TBL] [Abstract][Full Text] [Related]
39. Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillation.
Liu S; Li X; Shi Q; Hamilton M; Friend K; Zhao Y; Horblyuk R; Hede S; Shi L
Curr Med Res Opin; 2018 Mar; 34(3):415-421. PubMed ID: 28945114
[TBL] [Abstract][Full Text] [Related]
40. Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial.
Singer DE; Hellkamp AS; Yuan Z; Lokhnygina Y; Patel MR; Piccini JP; Hankey GJ; Breithardt G; Halperin JL; Becker RC; Hacke W; Nessel CC; Mahaffey KW; Fox KA; Califf RM;
J Am Heart Assoc; 2015 Mar; 4(3):e001349. PubMed ID: 25736441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
